TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00225641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-scan, CEA, X-ray of lungs
Description: Arm 1: 6, 12, 18, 24 and 36 months after surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT-scan, CEA, X-ray of lungs
Description: Arm 2: 12 and 36 months after surgery
Study: NCT03114345

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of interface pressure
Description: A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
Study: NCT03992482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
Study: NCT03114345

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of micro-vascularization related parameters
Description: A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
Study: NCT04795869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02451696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
Study: NCT00351117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: SJW in capsule form 300 mg PO TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: lactose in gelatin capsule that same as St. John's wort
Study: NCT01686217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K ER
Description: oral extended release (ER) at three dosing levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP015K IR
Description: oral immediate release (IR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP015K IR
Description: oral immediate release (IR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP015K IR
Description: oral immediate release (IR)
Study: NCT02877537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Description: before and after bronchodilation
Study: NCT01214239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: once a day
Study: NCT01816789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Study: NCT02877537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Description: before and after bronchodilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Description: before and after bronchodilation
Study: NCT04454996

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Chang 'an II Recipe
Description: This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Study: NCT01816789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buserelin
Study: NCT00834613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 750 mg Tablets
Description: 1 x 750 mg, single-dose fed
Study: NCT03793816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiZactTM Open Sealer/Divider
Description: The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiZactTM Open Sealer/Divider
Description: The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
Study: NCT00834613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER 750 mg Tablets
Description: 1 x 750 mg, single-dose fed
Study: NCT04042402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PHXC
Description: Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
Study: NCT00686868

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody
Study: NCT01164540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (AZD4522)
Description: Oral dose (od) 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose (od)
Study: NCT03310827

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized Nutrition
Description: Diet plan based on nutrition-related gene test results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition
Description: Diet plan based on nutrition-related gene test results
Study: NCT03176758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Block
Description: Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: 1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
Study: NCT00686868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: fully human anti-CD20 monoclonal antibody
Study: NCT02328040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Insulin monotherapy via CL
Description: In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin and insulin/novolog via CL
Description: In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
Study: NCT03214237

Intervention type: OTHER
Intervention: no intervention - cross-sectional observational only
Description: no intervention - cross-sectional observational only
Study: NCT03328390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: 15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: 15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
Study: NCT00486993

Intervention type: BEHAVIORAL
Intervention: Dietary and nutritional modification

Intervention type: BEHAVIORAL
Intervention: Stop smoking

Intervention type: BEHAVIORAL
Intervention: Regular physical activities

Intervention type: BEHAVIORAL
Intervention: Weight reduction to normal ranges

Intervention type: BEHAVIORAL
Intervention: Regular intake of polyphenols, esp. from Ilex paraguayensis
Study: NCT01326351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative injection therapy
Description: Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needle injection
Description: Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
Study: NCT04161950

Intervention type: OTHER
Intervention: Assessment of the safety and validity of echoendoscope
Description: 1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment

Intervention type: OTHER
Intervention: Assessment of the safety and validity of echoendoscope
Description: 1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment
Study: NCT04532996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychodynamic psychotherapy
Description: This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands.
Study: NCT00473616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7762
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous injection
Study: NCT00960154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
Study: NCT02786953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Promotion
Description: Behavioral intervention to improve sleep quality and duration.
Study: NCT00701194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention Foster Care (EIFC)
Description: The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Early Intervention Foster Care (EIFC)
Description: The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
Study: NCT00949091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally.
Study: NCT01376037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(r) ML Scanner (MLS)
Description: The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: inactive placebo laser device
Description: non-therapeutic light application
Study: NCT03176758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: A total knee arthroplasty surgery, which is not the intervention of interest

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: A total knee arthroplasty surgery, which is not the intervention of interest
Study: NCT02770469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistically and Culturally Tailored Information
Description: Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linguistically and Culturally Tailored Information
Description: Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management
Description: Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
Study: NCT02985203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Oral
Description: Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
Study: NCT01435317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANM T30 CR®-System
Description: Stimulation for 4-6h/day for a time of 1 year
Study: NCT03458663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ og ACTIV.A.C™ Therapy System.
Description: A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
Study: NCT04538196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resident education on documentation and coding
Description: Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
Study: NCT00586196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: 5 mg each day for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated cornstarch One capsule daily for 30 days
Study: NCT02025062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA and geriatric follow-up
Description: The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
Study: NCT04107259

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
Study: NCT00266773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic pain therapeutic interactive voice response (TIVR) system
Description: Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic pain therapeutic interactive voice response (TIVR) system
Description: Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
Study: NCT04401644

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel laser inferometry test for CORONA virus
Description: detection of virus particles by light absorbtion patterns.
Study: NCT01199900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study: NCT01978873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel + Androgen deprivation therapy
Description: Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.